Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.

Ann Rheum Dis · 2020 · PMC7286052 · PMID 32234715

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Tanezumab 2.5 mg improved pain and function in patients with moderate-to-severe OA, but did not reach statistical significance on the other co-primary end point, PGA-OA.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.